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ABSTRACT
Purpose: Despite recent improvements in therapeutic management of 
osteosarcoma, ongoing challenges in improving the response to chemotherapy 
warrants new strategies still needed to improve overall patient survival. Among 
new therapeutic approaches, zoledronic acid (ZOL) represents a promising adjuvant 
molecule to chemotherapy to limit the osteolytic component of bone tumors. However, 
ZOL triggers the elevation of heat shock proteins (Hsp), including Hsp27 and clusterin 
(CLU), which could enhance tumor cell survival and treatment resistance. We 
hypothesized that targeting CLU using siRNA or the antisense drug, OGX-011, will 
suppress treatment-induced CLU induction and enhance ZOL-induced cell death in 
osteosarcoma (OS) cells. 
Methods: The combined effects of OGX-011 and ZOL were investigated in vitro on 
cell growth, viability, apoptosis and cell cycle repartition of ZOL-sensitive or -resistant 
human OS cell lines (SaOS2, U2OS, MG63 and MNNG/HOS).
Results: In OS cell lines, ZOL increased levels of HSPs, especially CLU, in 
a dose- and time-dependent manner by mechanism including increased HSF1 
transcription activity. The OS resistant cells to ZOL exhibited higher CLU expression 
level than the sensitive cells. Moreover, CLU overexpression protects OS sensitive 
cells to ZOL-induced cell death by modulating the MDR1 and farnesyl diphosphate 
synthase expression. OGX-011 suppressed treatment-induced increases in CLU and 
synergistically enhanced the activity of ZOL on cell growth and apoptosis. These 
biologic events were accompanied by decreased expression of HSPs, MDR1 and HSF1 
transcriptional activity. In vivo, OGX-011, administered 3 times a week (IP, 20mg/
kg), potentiated the effect of ZOL (s.c; 50µg/kg), significantly inhibiting tumor growth 
by 50% and prolonging survival in MNNG/HOS xenograft model compared to ZOL 
alone.
Conclusion: These results indicate that ZOL-mediated induction of CLU can 
be attenuated by OGX-011, with synergistic effects on delaying progression of 
osteosarcoma.
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INTRODUCTION
Osteosarcoma (OS) is the most common primary 
malignant bone tumor in both children and young adults 
with a peak of incidence at 18 years [1, 2]. The tumor 
generally develops on the average part of the long bones 
(femur and tibia), at the vicinity of an articulation, mainly 
the knee or the shoulder. Current therapeutic protocols 
consist in neoadjuvant poly-chemotherapy associated 
with conservative surgery. The long-term survival rate 
is 60% to 75% at 5 years for patients with localized 
tumor but drastically goes down to 25% if pulmonary 
metastases are detected at diagnosis. However, patients 
who do not respond to these conventional therapies have 
a poor prognosis. To significantly improve survival in 
children with OS, new therapeutic strategies targeting 
the molecular basis of OS and treatment resistance are 
required.
Zoledronic acid (ZOL), the second generation of 
nitrogen-containing bisphosphonates (N-BPs), represents 
a promising alternative to treat OS. N-BPs are stable 
synthetic analogues of endogenous pyrophosphate (PPi) 
[3]. N-BPs induces osteoclast apoptosis by inhibiting 
enzymes of the mevalonate pathway, especially farnesyl 
diphosphate synthase (FDPs) [4, 5]. ZOL is one of the 
most potent inhibitors of bone resorption in clinical use 
to treat osteoporosis and other osteoclast-mediated bone 
diseases such as primary bone tumors. Moreover, several 
studies using bisphosphonates especially N-BPs, have 
demonstrated promising results by selectively targeting 
OS tumor cells [6-8]. We have previously shown that 
ZOL is able to delay tumor progression, to prevent 
tumor relapse compared with chemotherapy alone and 
to prevent osteolytic lesions in preclinical models of OS 
[9]. Our results have provided the rationale supporting the 
French randomized phase III clinical protocol OS2006 
(Clinicaltrials.gov NCT00470223), which combines ZOL 
with conventional therapy for adult and pediatric patients. 
Since then, other fundamental or preclinical studies have 
confirmed the beneficial effect of BPs in OS [6, 10, 11]. 
Indeed, ZOL directly affects the proliferation and survival 
of OS tumor cells in vitro [6, 12-14], making of ZOL an 
attractive therapy for the treatment of OS, targeting both 
tumor cells and bone microenvironment.
However, ZOL as a potential clinical application 
suggests an extensive and prolonged contact of cancer 
cells with this N-BP, which is localized and stored in 
tumor-bone microenvironment [15]. This continued 
exposure could increase the risk of resistance development 
[16]. Indeed, despite the widely use of bisphosphonates 
in the clinical management of cancer, few studies have 
reported ZOL-resistance development in cancer cells and 
that deserve to be explored. Development of treatment 
resistance is a common feature of most malignancies and 
the underlying basis for most cancer deaths. Treatment 
resistance evolves, at least, from selective pressures of 
treatment that collectively increase the apoptotic rheostat 
of cancer cells. Usually, the molecular mechanisms 
underlying resistance include overexpression of efflux 
pumps, inhibition of apoptosis (overexpression of anti-
apoptotic members of the bcl-2 protein family), increased 
DNA damage repair, and alteration of drug targets [17] 
and cytoprotective chaperone networks [18, 19]. Indeed, 
several cytoprotective chaperones such as Heat Shock 
Protein-27 (Hsp27) or clusterin (CLU) are reported to play 
a protective function in tumor cells under stress condition 
such as conventional or targeted therapies [20, 21].
CLU is a heterodimeric stress-induced 
cytoprotective chaperone that inhibits protein aggregation 
in a manner analogous to small HSPs, and its promoter 
contains a 14-bp element recognized by the transcription 
factor HSF1 [22]. CLU is ubiquitously expressed but at 
variable levels depending on many severe physiological 
disturbances, including tumor formation. In human OS, 
CLU levels are overexpressed in OS to a variable extent, 
especially after conventional therapy and could be a 
valuable marker of aggressive extraosseous osteosarcoma 
[23]. Experimental and clinical studies associate CLU 
with development of treatment resistance, where CLU 
suppresses treatment-induced cell death in response to 
conventional chemotherapy, targeted therapies or radiation 
[19, 21, 24-27]. Overexpression of CLU in OS indicates 
drug resistance to conventional therapies [23, 27] and 
over-expression of CLU in prostate cancer cells accelerates 
progression after hormone- or chemo-therapy [19, 24], 
identifying CLU as an anti-apoptotic gene up-regulated by 
treatment stress that confers therapeutic resistance. OGX-
011 is a second-generation phosphorothioate antisense 
oligonucleotide currently in late stage clinical development 
that potently inhibits CLU expression and enhances the 
efficacy of anticancer therapies in various human cancers 
[28, 29]. While targeting CLU synergistically enhances the 
cytotoxic effects of chemotherapy, a role for CLU has not 
been characterized in the context of ZOL treatment and 
resistance.
In the present study, we set out the hypothesis 
that ZOL induces a heat shock response with increased 
HSF1 activity and subsequently CLU expression, which 
functions as inhibitor of treatment-induced apoptosis, 
enhancing emergence of treatment resistance. Based on 
these data, knockdown of CLU using OGX-011 could 
potentiate the effect of zoledronic acid in osteosarcoma 
treatment.
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RESULTS
Zoledronic acid induces expression of clusterin in 
osteosarcoma cells in vitro and in vivo
First we assessed the effects of ZOL treatment on 
CLU expression in vivo in HOS-MNNG osteosarcoma 
xenografts using immunohistochemistry (Fig. 1A). Once 
tumors became palpable, mice were treated with ZOL 
and tumors were harvested for immunohistochemical 
analysis. While ZOL rapidly and significantly induced 
CLU expression (18h after treatment; Supp. Fig.1), CLU 
expression increased 2.5-fold after treatment with ZOL 
(***, p<0.001) compared with vehicle treated tumor after 
3 weeks of treatment (Fig. 1A), suggesting that ZOL 
treatment induced a stress response characterized by 
this increase of CLU expression. In addition, increased 
expression of CLU is durable 7 days after ZOL withdrawal 
(Supp. Fig. 1).
To confirm these in vivo results, dose-dependent 
effects of ZOL on the expression of CLU mRNA and 
protein levels were evaluated in a panel of human 
osteosarcoma cell lines (MNNG/HOS, MG63 and 
SaOS2). ZOL significantly increased CLU mRNA level 
in a dose-dependent manner depending of the tumor cell 
lines (Fig. 1B). CLU protein levels also increased in a 
dose-dependent manner after ZOL treatment in all tested 
osteosarcoma cell lines, as analyzed by western-blotting 
(Fig. 1C). 
Figure 1: ZOL induces CLU expression in osteosarcoma in vitro and in vivo. A, HOS-MNNG tumor cells were injected in 
paratibial site. Once tumors were palpable, mice were randomly assigned to vehicle (PBS) or ZOL (50ug/kg, s.c.) three times per week for 3 
weeks. Tumors were collected after 3 weeks and CLU expression was evaluated by immunohistochemical analysis. Specimens were scored 
and estimated in % positive cells. B, human OS cells (MG63, MNNG/HOS and SaOS2) were treated with ZOL at the indicated doses for 
48h. C, mRNA extracts were analyzed by real-time PCR for CLU. Protein extracts were analyzed by western blotting for CLU and vinculin 
expression. All experiments were repeated at least three times. ***, p<0.001; ** p<0.01.
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ZOL-resistant cells overexpress CLU and CLU 
overexpression protects osteosarcoma tumor cells 
from ZOL inhibitory effect
As CLU is overexpressed after ZOL treatment and is 
known to confer resistance to treatment in various cancers, 
we hypothesized that CLU could be involved in the 
emergence and maintenance of resistance of osteosarcoma 
cells to ZOL treatment. Based on this hypothesis, MG63 
and HOS-MNNG tumor cells were cultured in presence 
of increasing concentration of ZOL for 6 months to obtain 
ZOL-resistant cells, called MG63R and HOS-MNNG-R 
cells. After this time, the selected cells were ‘pooled’, in 
order to avoid clonality. We first compared the sensitivity 
of MG63 and HOS-MNNG sensitive cells versus MG63R 
and HOS-MNNG-R cells in presence of ZOL. While ZOL 
treatment significantly inhibited cell viability of MG63 
sensitive cells in a dose-dependent manner, no significant 
effect was observed on MG63R (Fig. 2A, right panel), 
showing that these cells became completely resistant to 
ZOL at the tested doses. The same results were obtained 
with HOS-MNNG-R cells (Supp. Fig. 2A). Then, we 
observed that MG63R exhibited a higher CLU expression 
at both RNA and protein level than MG63 sensitive cells 
(Fig. 2B), suggesting an association between CLU levels 
and the resistance to ZOL in OS cells.
Then, we tried to re-sensitize resistant cells to 
ZOL treatment by knocking down CLU using OGX-011 
antisense oligonucleotide (ASO), a specific CLU inhibitor 
(Fig. 2C and D). First we observed that MG63R cells (in 
red) treated with control ScrB are still resistant to ZOL 
treatment compared with MG63 sensitive cells treated 
with ScrB ASO (in green; Fig. 2C). However, CLU 
inhibition using OGX-011 significantly but partially re-
sensitzed MG63R tumor cells (in blue) to ZOL inhibitory 
effect by decreasing cell viability by 25% compared with 
MG63R treated with ScrB ASO (Fig. 2C). Moreover, 
MG63 sensitive cells treated with OGX-011 (in violet) are 
more sensitive to ZOL treatment than the MG63 sensitive 
Figure 2: CLU induced by ZOL treatment protects tumor cells and leads to ZOL resistance. MG63 cells were treated with 
increased doses of ZOL for 6 months to become resistant to ZOL (MG63R or MG63 resist.). After this time, the selected cells were ‘pooled’, 
in order to avoid clonality. A, MG63R and MG63 were treated with ZOL for the indicated doses for 48h. Cell growth was determined by 
crystal violet and compared with control. B, mRNA extracts (left panel) and protein extracts (right panel) of MG63 versus MG63R were 
analyzed by real-time PCR or by western blotting for CLU and vinculin expression. C, MG63 and MG63R cells were treated twice with 
300nM OGX-011 or control ScrB ASO, followed by the indicated concentration of ZOL for 48h. Cell growth was determined by crystal 
violet and compared with control. D, MG63 and MG63R cells were treated twice with 300nM OGX-011 or control ScrB ASO. mRNA 
extracts (left panel) and protein extracts (right panel) of MG63 versus MG63R were analyzed by real-time PCR or by western blotting for 
CLU and vinculin expression. All experiments were repeated at least three times. *** p<0.001; ** p<0.01; * p<0.05.
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cells treated with ScrB ASO (in green), suggesting a 
benefit effect of combination of OGX-011 with ZOL 
by inhibiting CLU expression (Fig. 2C and D). These 
results were confirmed by clonogenic assay in MG63 
and HOS-MNNG resistant cells (Supp. Fig. 2B). These 
results suggest that CLU is involved in the emergence of 
resistance to ZOL. Moreover, CLU knock-down prevents 
this emergence of resistance and enhance ZOL activity to 
inhibit OS cell growth.
Confirming the idea that CLU confers resistance 
to ZOL, we then transiently overexpressed CLU in 
osteosarcoma cells. CLU mRNA and protein levels 
Figure 3: Clusterin protects tumor cells from ZOL-induced effects via a regulation of HSF1 activity and MDR1 
expression. A, left panel, MG63 cells were transiently transfected with HSE-luciferase plasmid, followed by 10μM ZOL treatment for 
48h. Cells were harvested and HSE-luciferase activity was evaluated and represented in arbitrary units per μg of protein. Middle and right 
panels, mRNA and protein extracts of MG63 and MG63R cells were analyzed for CLU, MDR1, FDPs, Hsp27 and Actin expression by 
qPCR and western blotting, respectively. B, left panel, MG63 cells were transiently transfected with indicated concentrations of CLU-
plasmid (Total amount of plasmid DNA transfected was normalized to 0.75μg per well by the addition of an empty vector), followed by 
transfection of HSE-luciferase plasmid for 48h. Cells were harvested and HSE-luciferase activity was evaluated and represented in arbitrary 
units per μg of protein. Middle panel, MG63 cells were transiently transfected to overexpress CLU (MG63-CLU) compared with empty 
vector (MG63-empty) and mRNA extracts were analyzed for CLU, MDR1, FDPs and Hsp27 expression. Right panel, Protein extracts 
were analyzed for CLU, HSF1 and Actin expression by western blotting. C, MG63 cells were transiently transfected with HSE-luciferase 
plasmid, followed by 300nM OGX-011 or ScrB ASO twice for 48h. Cells were harvested and HSE-luciferase activity was evaluated and 
represented in arbitrary units per μg of protein. D, MG63R and MG63 cells were treated twice with 300nM OGX-011 or ScrB for 48h. Left 
panel, mRNA extracts were analyzed for MDR1 and FDPs expression. Right panel, protein extracts were analyzed for CLU, HSF1, FDPs, 
MDR1 and Actin expression by western-blotting. All experiments were repeated at least three times. ***, p<0.001; *, p<0.05.
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were analyzed osteosarcoma cells (Supp. Fig. 2C). CLU 
mRNA expression was significantly increased to 4.5-
fold compared to control cells and confirmed by western 
blot analysis (Supp. Fig. 2C). Then, the response to ZOL 
treatment was evaluated in these osteosarcoma CLU-
overexpressed cells versus the control cells by a cell 
viability assay. While control cells responded to ZOL 
treatment in a dose-dependent manner, ZOL decreased 
also the cell viability in a dose-dependent manner in cells 
CLU-overexpressing cells (Supp. Fig. 2C). However, cells 
CLU-overexpressed cells were significantly less sensitive 
to ZOL treatment than the control cells, demonstrating that 
CLU overexpression protects osteosarcoma cells to ZOL-
induced cytotoxicity (Supp. Fig. 2C).
CLU regulates the resistance phenotype of 
osteosarcoma cells
Because HSF1 is a master regulator of the heat 
shock response [30], we then evaluate the effect of ZOL 
treatment on HSF1 activity and HSPs expression. First, 
we used the Heat Shock Element (HSE) reporter designed 
to monitor the activity of heat shock response through 
measuring the transcriptional activity of HSF1, leading to 
induction of Hsps and CLU expression. We first verified 
that overexpression of HSF1 increased HSE luciferase 
activity (Supp. Fig. 3A). Moreover, it is well known that 
exposure of cells to elevated temperatures such as 42°C 
activates HSF1 binding to HSE, which induces HSF1-
driven reporter activity (Supp. Fig 3B). Then, we found 
that ZOL significantly induced HSE luciferase activity 
suggesting that ZOL increased HSF1 transcriptional 
activity (Fig. 3A, left panel) and CLU expression (Fig. 
1). In MG63R cells, enhanced CLU expression is 
accompanied with increased-expression level of Hsp27 
compared with MG63 sensitive cells (Fig. 3A, middle 
panel), suggesting an increase of heat shock response 
induced by HSF1. 
We know that CLU overexpression protects tumor 
cells from ZOL-induced cell death (Supp. Fig. 2C), and 
we found that overexpression of CLU also increased 
HSF1 activity in a dose dependant-manner (Fig. 3B, left 
panel) followed by increase of Hsp27 expression (Fig. 3B, 
middle panel), without affecting HSF1 expression (Fig. 
3B, right panel). Moreover, CLU knockdown using OGX-
011 significantly decreased HSF1 transcriptional activity 
(Fig. 3C) without affecting HSF1 expression (Fig. 3D, 
right panel), which was also confirmed by using specific 
siRNA targeting CLU (Supp. Fig. 3C), while knock-down 
of HSF1 using siRNA decreased CLU expression (Supp. 
Fig. 3C). All These data suggest a feed-forward regulation 
of HSF1 by CLU as we previously reported in prostate 
cancer [31].
Resistance to ZOL treatment involves different 
biological processes including increase expression of 
MDR1 and FDPs [32], as observed in MG63R tumor cells 
compared with MG63 sensitive cells (Fig. 3A, middle 
and right panel) and in HOS-MNNG-R compared with 
HOS-MNNG sensitive cells (Supp. Fig. 3D). Surprisingly, 
this increase of MDR1 and FDPs expressions correlates 
with the increase of CLU expression in MG63R cells. 
Moreover, overexpression of CLU in MG63 cells 
also leads to significant increase of MDR1 and FDPs 
expressions (Fig. 3B, middle panel), suggesting that CLU 
could regulate MDR1 and FDPs expressions. MDR1 is 
reported to be transcriptionally regulated directly by HSF1 
with the presence of HSE sequence in MDR1 promoter 
[33], and we effectively confirm that HSF1 knockdown 
using siRNA significantly reduced MDR1 expression 
while FDPs expression was not affected (Supp. Fig. 3E). 
Interestingly, CLU inhibition using OGX-011 significantly 
reduced MDR1 expression in MG63R, but did not affect 
FDPs expression at transcriptional level compared with 
MG63R treated with ScrB ASO (Fig. 3D, left panel), 
while both FDPs and MDR1 expressions were decreased 
at protein level (Fig. 3D, right panel). All these results 
suggest that CLU indirectly regulates MDR1 expression at 
transcriptional level by regulating HSF1 activity (Fig. 3C). 
However, CLU inhibition does not affect FDPs expression 
at transcriptional level but seems to regulate FDPs at 
protein level probably by its chaperone activity.
OGX-011 enhances ZOL induced apoptosis in 
osteosarcoma cell lines
Since ZOL induces up-regulation of CLU and CLU-
functions as mediator in treatment resistance [28, 29, 34], 
we next evaluated whether CLU knockdown potentiated 
the effect of ZOL treatment. To determine whether this 
effect was additive or synergistic, the dose-dependent 
effects with constant ratio design and the combination 
index (CI) values were performed and calculated 
according to the Chou and Talalay median effect 
principal [35]. Figure 4A shows the dose response curve 
(combination treatment, OGX-011 or ZOL monotherapy) 
and the combination index plots, indicating that OGX-
011 synergistically enhances the effect of ZOL on HOS-
MNNG tumor cell growth (Fig. 4A). These results were 
confirmed in MG63, SaOS2 and U2OS cells (Supp. Fig. 
4). 
Then we performed a colony formation assay to 
evaluate capabilities to recover after 2 days of OGX-
011 +/-ZOL treatment. While neither OGX-011 nor ZOL 
did not change the number of colonies compared with 
control ScrB ASO (Fig. 4B), the combination of OGX-
11 with ZOL significantly decreased the colony formation 
compared with each single drug alone (Fig. 4B). 
Moreover, OGX-011 potentiates the effect of ZOL 
inhibitor to induce apoptosis (Fig. 4C and D). Flow 
cytometric analysis shows that apoptotic rates (subG1 
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fraction) significantly increased (p<0.001) when OGX-011 
is combined with ZOL (38.4%) compared to control ScrB 
(1.8%), OGX-011 (10.8%), control ScrB ASO + ZOL 
(9.3%; Fig. 4C). The significant increase of caspase-3/7 
activity confirms that OGX-011 sensitizes cells to ZOL 
inhibition with increased apoptotic rates (Fig. 4D).
OGX-011 potentiates zoledronic acid activity in 
MNNG/HOS xenografts in vivo
The effects of combined treatment with OGX-
011 and ZOL were evaluated in HOS-MNNG xenograft 
tumors. Athymic mice were injected with human 
osteosarcoma HOS-MNNG cells in paratibial site. Once 
tumors were palpable, mice were randomly assigned 
to vehicle control, ZOL + ScrB ASO, or ZOL + OGX-
011 groups. In a first in vivo experiment, we confirmed 
that ScrB and OGX-011 do not have effect on tumor 
growth compared with tumor control group (Supp. Fig. 
5A and B). In a second experiment, all animals treated 
with ZOL + OGX-011 (n=8) had significant delays in 
tumor growth compared with other groups starting at day 
15 (respectively 196 mm3 for ZOL + OGX-011 versus 
451.3 mm3 for control and 404.9 mm3 for ZOL + ScrB 
ASO) and after 36 days (respectively 997.2 mm3 for ZOL 
+ OGX-011 versus 2023.6 mm3 for control and 1954.2 
mm3 for ZOL + ScrB ASO; ***, p<0.001; Fig. 5A). Until 
day 27, ZOL + ScrB shows marginal but not significant 
decrease of tumor growth compared with control group 
(respectively 1368.5 mm3 and 1649.9 mm3 at day 27). 
Moreover, at individual level, 0 out of 8 mice developed 
tumor with volume over 1000mm3 at day 30, while all 
mice in control and ZOL + ScrB ASO groups exhibited 
tumor volume over 1000mm3 (Fig. 5B). Overall survival 
was significantly prolonged in mice treated with combined 
ZOL + OGX-011 (p<0.001; Fig. 5C). By day 42, all 
Figure 4: CLU knockdown enhances effects of ZOL treatment in OS cells. A, Dose-dependent effects and Combination Index 
(CI) values calculated by CalcuSyn software were assessed in MNNG/HOS cells treated for 48 hours with OGX-011 alone, ZOL alone, or 
combined treatment at indicated concentration with constant ratio design between both drugs. Cell growth was determined by crystal violet. 
The CI for ED50, ED75 and ED90 was respectively 0.084, 0.104 and 0.162 indicating a synergistic effect (lower than 1) of CLU inhibition 
combined with ZOL. B, osteosarcoma cells were treated with 300nM OGX-011 or ScrB ASO +/- 1μM ZOL for 2 days, and then plated at 
clonal density for colony counts. C, HOS cells were treated with 300nM OGX-011 or ScrB ASO +/- 1μM ZOL for 2 days and the proportion 
of cells in subG1 was determined by propidium iodide staining. D, Cells were harvested, and Caspase-3/7 activity was determined on the 
cell lysates and the results are expressed in arbitrary units and corrected for protein content (D). All experiments were repeated at least three 
times. *** p<0.001; ** p<0.01; * p<0.05.
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mice died or were euthanized due to high tumor burden 
in control and in ZOL + ScrB groups as compared with 
the combined ZOL + OGX-011 group, where all mice 
were still alive after 46 days. These data demonstrate that 
targeting CLU using OGX-011 potentiates the effects of 
ZOL to significantly inhibit tumor growth and prolongs 
survival in osteosarcoma xenograft model.
Consistent with in vitro findings, 
immunohistochemical analysis reveals decreased ZOL-
induced CLU, and Ki67 expression after treatment 
with combined ZOL + OGX-011 compared with other 
groups (Fig. 5D), corroborating the in vitro results. Ki67 
Figure 5: OGX-011 potentiates ZOL activity in MNNG/HOS osteosarcoma xenograft model. Mice were treated twice a 
week with 50μg/kg ZOL and 15mg/kg OGX-011 starting when tumors were palpable as described in M&M. The mean tumor volume (A) 
and individual tumor volume (B) were compared between the 3 groups ± SEM (n=8). ***, p<0.001. C, in Kaplan-Meier curve, cancer-
specific survival was compared between the 3 groups over a 46-d period. ***, p<0.001. D, tumors were collected and CLU, Ki67, and 
cleaved-caspase-3 were evaluated by immunohistochemical analysis. Specimens were scored and estimated in percentage of positive cells. 
The control group corresponds to the mice bearing tumor that did not receive any treatment. This group only received vehicle. * p<0.05; 
*** p<0.001.
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expression correlates with the mean tumor volume (Fig. 
5A and D). Indeed, ZOL + OGX-011 treatment delayed 
tumor growth and decreased Ki67 expression compared 
with other groups exhibiting both high tumor volume and 
elevated Ki67 expression. Additionally, tumors treated 
with ZOL + OGX-011 combination had significant higher 
apoptosis rates compared with other groups as shown by 
increased cleaved-Caspase-3 staining (Fig. 5D). These 
data suggest that decreases in tumor progression in ZOL 
+ OGX-011 treated tumors result from both reduced 
proliferation rates as well as increased apoptosis rates.
CLU knock-down does not ameliorate ZOL-
induced bone prevention
ZOL is known to prevent bone lesions and indirectly 
inhibit tumor growth by blocking the vicious cycle 
between bone resorption and tumor cells within the tumor-
bone microenvironment [36]. That is why we first evaluate 
the effect of combined treatment on bone lesions on tumor-
bearing tibia in HOS-MNNG xenograft model. The bone 
micro architecture parameters of the tumor-bearing tibia, 
from MNNG/HOS xenograft model treated with ZOL + 
SCRB, ZOL + OGX-011 or vehicle have been measured 
using X-ray, microCT and 3D reconstruction models (Fig. 
6A). Data analysis revealed a decrease with ZOL treatment 
of the tumor-associated osteolysis that we usually observe 
on the tumor-bearing bone (Fig. 6A and B). An extensive 
analysis of multiple bone parameters revealed a strong 
and significant increase of tumor-associated bone quality 
in the ZOL treated groups (ZOL + SCRB, ZOL + OGX-
011) compared to control group. Indeed, ZOL treatment 
increased significantly the trabecular bone volume 
relatively to the tissue volume (BV/TV) from 4.2% to 
25.2% and 22.5% respectively in ZOL + SCRB and ZOL + 
Figure 6: Effect of combination treatment on bone prevention in MNNG/HOS osteosarcoma xenograft model. A, 
representative radiographic, microCT, and 3D model images of the tumor-bearing tibia taken ex vivo, from HOS-MNNG xenograft model 
treated with OGX-011 (15mg/kg) + ZOL (50μg/kg), ScrB ASO + ZOL or control (Ctrl; ScrB + PBS). B, MicroCT quantification of 
the specific trabecular bone volume (BV/TV (%)) (upper left panel), trabecular thickness (Tb.Th (mm)) (upper right panel), trabecular 
separation (Tb.Sp (mm)) (lower left panel) and trabecular number (Tb.N (/mm)) (lower right panel) were calculated on the tibia of tumor-
bearing mice of the different groups. C, TRAP expression was evaluated by immunohistochemical analysis. Specimens were scored and 
the surface occupied (in %) by osteoclast was determined by ImageJ in the delimited ROI. *** p<0.001; ** p<0.01; n.s., not significant.
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OGX-011 groups, the trabecular number (Tb.N) from 0.56 
to 2.64 and 2.6mm, the trabecular thickness (Tb.Th) from 
0.07 to 0.093 and 0.085mm and decreased the trabecular 
separation (Tb.Sp) from 0.59 to 0.3 and 0.31mm (Fig. 6B). 
Histological analysis of the tumor-bearing bone with 
TRAP staining revealed a significant decreased of surface 
occupied by osteoclasts compared with control group in 
presence of ZOL (ZOL + SCRB and ZOL + OGX-011 
groups; Fig. 6C). However, no significant difference 
was observed between ZOL + SCRB and ZOL + OGX-
011 groups. OGX-011 does not improve ZOL-induced 
bone prevention of tumor-bearing tibia compared to ZOL 
alone; suggesting that the significant decrease of tumor 
growth is due to a direct inhibition of tumor cells and not 
via inhibition of bone prevention. Consequently, OGX-
011 seems to potentiate the direct effect of ZOL to inhibit 
tumor cells in HOS-MNNG xenograft model.
DISCUSSION
Cancer cells express high levels of molecular 
chaperones and pirate the protective functions of 
HSF1 to support their transformation [37]. Molecular 
chaperones help cells cope with stress-induced protein 
aggregation, and play prominent roles in cell signaling and 
transcriptional regulatory networks. A growing enthusiasm 
for therapeutic modulation of this proteostasis network 
highlights Hsp’s and CLU as rational targets because of 
their multifunctional roles in signaling and transcriptional 
networks associated with cancer progression and treatment 
resistance. In this study, we set out to evaluate the role 
of CLU in this heat shock response in OS since CLU is 
dramatically induced by ZOL treatment and CLU inhibitor 
is currently in phase III clinical Trial in prostate cancer. We 
report that ZOL induces a stress response with activation 
of the transcription factor HSF1 and subsequent increased 
levels of CLU. This heat shock response likely enhances 
emergence of treatment resistance, as Hsp27 inhibition 
using siRNA which attenuates ZOL-mediated Hsp27 
expression and potentiates the effect of ZOL in vitro [20].
CLU expression is rapidly up-regulated in various 
cancer tissues, including osteosarcoma [23]. Previous 
studies have also linked CLU expression with induction 
and progression of many cancers [29]. Consistent with 
these accumulated findings [38], inhibition of CLU using 
OGX-011 synergistically enhances conventional as well as 
molecular targeted therapies in cancer preclinical models 
[31, 39]. Here, we show that ZOL increases CLU levels 
by enhancing HSF1 transcriptional activity both in vitro 
and in vivo, while OGX-011 inhibits ZOL induced CLU 
expression. We also found that CLU silencing abrogates, 
while CLU overexpression enhances, ZOL-induced HSF1 
transcriptional activity, suggesting a role for CLU in the 
regulation of HSF1 and the heat shock response itself, as 
reported in the literature [31]. This effect of CLU on HSF1 
activity is biologically relevant since CLU overexpression 
protects, while CLU silencing enhances, ZOL-induced 
cytotoxicity in OS cells. Consistent with our in vitro 
results, synergistic effects were also observed in vivo 
in HOS-MNNG xenograft models when OGX-011 was 
combined with ZOL. OGX-011 and ZOL combination 
significantly delays OS tumor growth and prolonged 
survival in HOS-MNNG xenograft model. 
ZOL is known to prevent bone lesions and 
indirectly inhibit tumor growth by blocking the vicious 
cycle between bone resorption and tumor cells within the 
tumor-bone microenvironment [36]. Indeed, by blocking 
osteoclasts, ZOL inhibits the release of growth factor 
(TGF-β, IGF-1…) trapped in bone matrix and liberated 
during bone resorption to activate proliferation of tumor 
cells. In our experiment, OGX-011 does not improve 
ZOL-induced bone prevention of tibia bearing-tumor in 
HOS-MNNG xenograft model compared to ZOL alone; 
suggesting that the significant decrease of tumor growth 
after combined treatment is due to a direct inhibition of 
tumor cells and not via inhibition of bone prevention. 
Consequently, OGX-011 strongly potentiates the direct 
effect of ZOL to inhibit tumor cells in OS xenograft 
model. Indeed, decreased Ki67 expression and increased 
apoptotic rates with combined ZOL and CLU inhibition 
suggests that delayed tumor progression resulted from both 
inhibition of tumor proliferation and enhanced treatment-
induced apoptosis. These in vivo data are consistent 
with the in vitro data, and are the proof of principle to 
combine OGX-011 with ZOL as new therapeutic strategy 
in treatment of OS.
Molecular mechanisms of acquired drug resistance 
often involve expression of one or more energy-
dependent transporters that detect and eject anticancer 
drugs from cells [17]. Studies on mechanisms of cancer 
drug resistance have yielded important information about 
how to circumvent this resistance to improve cancer 
treatment. So far, few studies have reported molecular 
mechanisms underlying N-BPs-induced resistance. Kars 
et al. reported that increased ABC transporters expression 
(BCRP and LRP), as well as up-regulation of the anti-
apoptotic Bcl-2 gene were found in ZOL-resistant breast 
cancer cells as compared to sensitive cells [40]. In the 
current study, we show for the first time an increase of 
another ABC transporter, MDR1 in ZOL-resistant MG63 
and HOS-MNNG cells compared with sensitive cells. 
MDR1 promoter has been shown to contain heat shock 
elements (HSE) sequence [33], and to be transcriptionally 
regulated by HSF1 [41]. Consequently, inhibition of heat 
shock factor response using quercetin decreased MDR1 
expression [41]. We found that ZOL induced HSF1 
activity thus increasing MDR1 expression, while HSF1 
knockdown using siRNA reduced MDR1 expression. 
While CLU is known to be transcriptionally activated 
by HSF1 [29, 31], in this study we also show that CLU 
exerts a feed forward loop that in turn activates HSF1, 
and also maintain MDR1 expression. Indeed, transient 
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overexpression of CLU significantly increased MDR1 
expression. On the other hand, CLU knockdown using 
OGX-011 decreases HSF1 transcriptional activity, which 
subsequently leads to decreased MDR1 expression, similar 
to that observed after HSF1 knockdown. Collectively, 
these results highlight a biologically relevant feed-forward 
regulation loop of CLU on HSF1 activity and, indirectly 
on MDR1 regulation (Supp. Fig. 6).
Ory et al. described one other molecular mechanism 
of ZOL resistance in OS cells by indicating that prolonged 
treatment with ZOL increased FDPs expression [32], a 
critical enzyme involved in the mevalonate pathway that 
is inhibited by N-BPs, while Milone et al. contested this 
hypothesis [42]. In our study, we confirmed that ZOL-
resistant cells exhibited higher FDPs expression than the 
sensitive cells and, this result was correlated with increase 
CLU expression. However, we demonstrated that CLU 
does not affect FDPs expression at transcriptional level, 
but decreases FDPs expression at protein level suggesting 
that the molecular chaperone CLU could regulate 
FDPs pathway at protein level, and this need further 
investigations.
Moreover, several studies have reported a potential 
role of p38-MAPK pathway and/or its downstream 
target Hsp27 in the resistance of N-BPs treatment in 
preclinical models of breast cancer and osteosarcoma 
[10, 20, 43]. In our study we found that ZOL treatment 
induced HSF1 activity thus enhancing at least, Hsp27 
expression according with the literature. However, we 
also demonstrated that CLU, also induced by HSF1, 
regulates via the feed-forward loop, HSF1 activity and 
thus, indirectly regulates Hsp27 expression that could lead 
to other molecular mechanisms inducing resistance.
The variety of described molecular mechanisms 
underlying N-BPs-induced resistance could be attributed 
to the heterogeneity of tumor cells or the methods used 
for inducing resistance. We described some molecular 
mechanisms of resistance regulated by CLU, but it is not 
excluded that other more complex mechanisms take part in 
the emergence of ZOL resistance. Thus, the main problem 
is to determine which molecular mechanism is involved 
for each patient, in order to adapt the best therapy in the 
era of personalized medicine.
In addition to synergistically enhancing anti-tumor 
activity, combination therapy of OGX-011 + ZOL may 
also allow dose reduction strategies to reduce toxicity and 
undesirable side effects such as osteonecrosis of jaw that 
has been associated with ZOL in clinical trials and clinical 
use. In the present study, 50μg/kg ZOL monotherapy, 
corresponding to the dose used in young patients with OS 
in accord with the literature [44], showed marginal, non-
significant decreases in tumor volume but a significant 
effect on bone prevention; however, significant delays 
in tumor progression were seen at this dose when ZOL 
was combined with OGX-011, with no toxicity observed. 
Moreover, OGX-011 is a second-generation ASO with a 
long tissue half-life of ~7 days that suppresses CLU levels 
in vitro and in vivo. OGX-011 improved the efficacy 
of many varied anti-cancer therapies by suppressing 
treatment-induced CLU and the stress response [31] and 
increased pre-clinical activity in many xenograft models 
of cancer [29, 39, 45].
In summary, this paper helps define how stress 
induced by ZOL regulates CLU by induction of HSF1 
activity and, in turn, how CLU regulates HSF1 activity, 
cell survival, and treatment resistance. We demonstrate, 
for the first time, that CLU inhibition abrogates the 
heat shock response and synergistically potentiates the 
cytotoxic activity of ZOL directly on tumor cells, thus, 
preventing emergence of resistance. These observations 
are clinically relevant since CLU inhibitors are in phase III 
clinical trials in prostate cancer, and provide a framework 
for building new drug combinations built on mechanism-
based interventions to overcome drug resistance. The 
present study supports for the first time the development 
of targeted strategies employing OGX-011 in combination 
with ZOL to improve patient outcome in osteosarcoma.
MATERIALS AND METHODS:
Tumor cell lines
The human osteosarcoma cell lines MG63 (young 
male osteosarcoma), SaOS2 (young female osteosarcoma), 
U2OS (young female osteosarcoma from tibia origin) and 
MNNG/HOS (young female high grade osteosarcoma 
from femur origin transformed in vitro by N-methyl N’-
nitro-N-nitrosoguanidine treatment), were purchased from 
the American Type Culture Collection and maintained in 
DMEM (Invitrogen-Life Technologies, Inc.) supplemented 
with 5% fetal bovine serum and 2mmol/L L-glutamine. 
All cell lines were cultured in a humidified 5% CO2/air 
atmosphere at 37oC. All cell lines were passaged for less 
than 3 months after resurrection.
Therapeutic agents
ZOL, 1-hydroxy-2-(1H-imidazole-1-yl) ethylidene-
bisphosphonic acid supplied as the disodium salt by 
Novartis Pharma AG, was dissolved in PBS at 10mM 
stock solution and stored at -20°C.
Second-generation antisense (OGX-011) 
and scrambled (ScrB) oligonucleotides with a 
2′-O-(2-methoxy) ethyl modification were supplied 
by OncoGenexPharmaceuticals (Vancouver, 
British Columbia, Canada). OGX-011 sequence 
5′-CAGCAGCAGAGTCTTCATCAT-3′ corresponds to the 
initiation site in exon II of human CLU. The ScrB control 
sequence was 5′-CAGCGCTGACAACAGTTTCAT-3′. 
siRNA targeting HSF1 or CLU and siRNA control (siSCR) 
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were purchased from SantaCruz Biotechnology (Dallas, 
USA). Osteosarcoma cells were treated with siRNA or 
oligonucleotides using protocols described previously 
[39].
Cell proliferation and apoptosis assays
Osteosarcoma cancer cell lines were plated in 
DMEM with 5% FBS and treated with zoledronic acid 
at indicated concentration and time point, cell growth 
being measured using the crystal violet assay as described 
previously [46]. Detection and quantitation of apoptotic 
cells were done by Caspase-3 assay (described below). 
Each assay was repeated in triplicate. 
The combination index (CI) was evaluated 
using CalcuSyn dose effect analysis software (Biosoft, 
Cambridge, UK). This method, based on the multiple 
drug effect equation of Chou-Talalay [35], is suitable for 
calculating combined drug activity over a wide range of 
growth inhibition: CI =1, additivity; CI >1, antagonism; 
CI <1, synergism. CI was calculated at ED50 and ED75.
Caspase-3/7 activity was assessed 3 days after 
treatment using the kit CaspACE Assay System, 
Fluorometric (Promega, Madison, WI, USA). Fifty µg of 
total cell lysate were incubated with caspase-3 substrate 
AC-DEVD-AMC at room temperature for 4h and 
caspase-3 activity was quantified in a fluorometer with 
360nm excitation and 460nm emission.
Cell cycle analysis
Osteosarcoma cell lines were treated twice with 
300nM ScrB or OGX-011, followed by 1μM ZOL for 
48h, trypsinized, washed twice and incubated in PBS 
containing 0.12% Triton X-100, 0.12mM EDTA and 
100μg/ml ribonuclease A; 50μg/ml propidium iodide was 
then added to each sample for 20min at 4°C. Cell cycle 
distribution was analyzed by flow cytometry (Beckman 
Coulter Cytomics FC-500, Beckman, Inc., Miamai, FL), 
based on 2N and 4N DNA content. Each assay was done 
in triplicate.
Western blotting analysis
Samples containing equal amounts of protein 
(depending on the antibody, 5-50µg) from lysates of 
cultured tumor OS cell lines underwent electrophoresis 
on SDS-polyacrylamide gel and were transferred to 
nitrocellulose filters. The filters were blocked in PBS 
containing 3% BSA and 0.1% Tween at room temperature 
for 1h and blots were probed overnight at 4°C with primary 
antibodies (anti-clusterin, Santa Cruz Biotechnology, 
Dallas, TX, USA; anti-vinculin, Sigma-Aldrich Corp, 
St. Louis, MO, USA) to detect proteins of interest. After 
incubation, the filters were washed 3 times with washing 
buffer (PBS containing 0.1% Tween) for 5min. Filters 
were then probed with the secondary antibody coupled to 
horseradish peroxidase. Antibody binding was visualized 
with the enhanced chemiluminescence system (Roche 
Molecular Biomedicals).
Quantitative Reverse Transcription-PCR
Total RNA was extracted from cultured cells (after 
48h of treatment) using TRIzol reagent (Invitrogen Life 
Technologies, Inc.). Two μg of total RNA was reversed 
transcribed using the Transcriptor First Strand cDNA 
Synthesis Kit (Roche Applied Science). Real-time 
monitoring of PCR amplification of complementary DNA 
(cDNA) was performed using DNA primers (supplemental 
table S1) on ABI PRISM 7900 HT Sequence Detection 
System (applied Biosystems) with SYBR PCR Master 
Mix (Applied Biosystems). Target gene expression was 
normalized to GAPDH levels in respective samples as an 
internal standard, and the comparative cycle threshold (Ct) 
method was used to calculated relative quantification of 
target mRNAs. Each assay was performed in triplicate.
Luciferase assay
Osteosarcoma cells (2.5x105) were plated on six-
plates and transfected using lipofectin (6µL per well; 
Invitrogen Life Technologies, Inc.). The Heat Shock 
Element (HSE) reporter is designed to monitor the 
activity of heat shock response through measuring the 
transcriptional activity of HSF1. The total amount HSE 
plasmids DNA used were normalized to 1µg per well 
by the addition of a control plasmid. Ten µM zoledronic 
acid was added 8h after the transfection and for 48h. 
HSE-luciferase activity was measured using Dual-
Luciferase Reporter Assay System (Promega) with the aid 
of a microplate luminometer (TriStar LB-941 Berthold 
Technologies). All experiments were carried out in 
triplicate wells and repeated 3 times.
Animal Treatment
Five-week-old female Rj:NMRI-nude mice were 
anesthetized by inhalation of an isoflurane/air mixture 
(2%, 1L/min) before an i.m. inoculation of 2 × 106 
human MNNG/HOS osteosarcoma cells close to the tibia. 
Tumors appeared in contact with the tibia approximately 
8 days later and led to osteolytic lesions associated with 
development of pulmonary metastasis mimicking the 
human pathology. Once tumors were palpable, mice were 
randomly assigned (n=8) to vehicle, ZOL + ScrB ASO or 
ZOL + OGX-011 groups. ZOL (50μg/kg; formulation in 
PBS) was injected s.c. three times per week and OGX-011 
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or ScrB ASO (15mg/kg) was injected intra-peritoneally 
once daily for the first week and then three times per week. 
Each experimental group consisted of 8 mice. Tumor 
volume was measured three times weekly (length x width 
x depth x 0.5432). Data points were expressed as average 
tumor volume ± SEM. 
When tumor volume reached ≥10% of body 
weight, mice were sacrificed and tumors harvested for 
immunohistochemistry. Animal care and experimental 
protocols were approved by the French Ministry 
of Research and were done in accordance with the 
institutional guidelines of the French Ethical Committee 
protocol agreement number 1280.01 and under the 
supervision of authorized investigators. 
Immunohistochemistry
Immunohistochemical stains were performed on 
formalin-fixed and paraffin-embedded 3µm sections of 
tumor samples using adequate primary antibody, and 
the Ventana autostainer Discover XT (Ventana Medical 
System) with enzyme labeled biotin streptavidin system 
and solvent resistant 3,3’-diaminobenyidine Map kit. All 
comparisons of staining intensities were made at 200x 
magnifications.
Statistical analysis
All in vitro data were assessed using the Student 
t test and Mann-Whitney test. Tumor volumes of mice 
were compared using Kruskal-Wallis test. Overall survival 
was analyzed using Kaplan-Meier curves and statistical 
significance between the groups was assessed with the 
log-rank test (Graphpad Prism). Levels of statistical 
significance were set at P<0.05.
ACKNOWLEDGMENTS
This study was supported by L’Association pour la 
Recherche sur le Cancer, France (F.L).
Conflict of interest
The University of British Columbia has submitted 
patent applications, listing Dr. Gleave as inventor, on the 
antisense sequence described in this paper. This IP has 
been licensed to OncoGenex Technologies, a Vancouver-
based biotechnology company that Dr. Gleave has 
founding shares in. 
Abbreviations
OS   osteosarcoma
HSP   heat shock proteins
CLU   clusterin
HSF1   heat shock factor 1
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